What is Opko Health's market cap?

Opko Health (OPK) has a market capitalization of $936.3M and trades on NASDAQ.

What is Opko Health's revenue and profitability?

Opko Health generated $587.9M in trailing twelve-month revenue with a net loss of $72.9M, representing a net margin of -12.4%. Gross margin stands at 40.8%, with free cash flow of -$134.0M. These figures are based on the Q2 2026 filing.

Who are Opko Health's competitors?

Opko Health's key competitors include Quest Diagnostics, Bristol-Myers Squibb Co., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.

Who does Opko Health partner with?

Opko Health's notable partners include Pfizer Inc., Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Inc., and others.

What subsidiaries does Opko Health have?

Opko Health's subsidiaries include BioReference Health, LLC, ModeX Therapeutics, Inc., EirGen Pharma, Ltd., and others.

Where is Opko Health headquartered?

Opko Health is headquartered in United States of America and employs approximately 3,930 people. It has been publicly traded since 1995.

Opko Health

OPK

Opko Health Inc. is a diversified healthcare company focused on establishing leading positions in the global pharmaceutical and diagnostic markets.

Market cap

$936.31M-11.9%

Revenue$587.9M-11.5%

Net income-$72.9M+58.9%

Free cash flow-$134.0M+48.3%

EPS (diluted)-$0.09+64.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 27, 2026

Revenue$163.5MBeat by $32.3M EPS-$0.01Beat by $0.07

Read the full report

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full

Revenue$163.6M+4.3%

Gross profit$80.0M+62.0%

Operating income-$7.0M+88.4%

Net income-$8.4M+94.3%

EPS (diluted)-$0.01+94.7%

Balance sheet

See full

Total debt$49.9M-7.5%

Total equity$1.2B-8.7%

Total assets$1.8B-7.3%

Cash flow

See full

Operating cash flow-$43.5M+47.9%

CapEx$3.0M-8.5%

Free cash flow-$46.5M+46.4%

Valuation & ratios

Valuation

See full

Market cap$936.31M-11.9%

P/S1.6×0.0×

Profitability

See full

Gross margin40.8%+8.1pp

Operating margin-8.2%-3.5pp

Net margin-12.4%-4.3pp

FCF margin-22.8%-6.7pp

Returns & leverage

See full

Return on equity-5.9%-2.1pp

Debt / equity0×0.0×

Current ratio3.3×-0.1×

Segments

By geography

See full

US$88.8M—

IE$41.7M—

CL$16.4M—

ES$8.5M—

MX$7.0M—

By product

See full

Intellectual Property And Other$46.1M—

Transfer Of Intellectual Property And Other$46.1M+208%

Rayaldee$14.3M—

Competitors

By market cap

AbbVie$453.91B+36.3%

Merck & Co.$322.95B+53.0%

Bristol-Myers Squibb$127.75B+32.1%

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

Quest Diagnostics$25.6B+36.3%

Opko Health$936.3M-12.5%

Vanda Pharmaceuticals$313.9M+13.3%

Karyopharm Therapeutics$160.7M+326%

By revenue growth

ALN

Alnylam Pharmaceuticals+82.6%

Quest Diagnostics+9.9%

AbbVie+9.5%

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

Opko Health-11.5%

By net margin

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

Quest Diagnostics9.19%+0.2pp

AbbVie5.79%-1.5pp

Opko Health-12.4%+14.3pp

Profile

Opko Health Inc. is a diversified healthcare company focused on establishing leading positions in the global pharmaceutical and diagnostic markets. The company leverages proprietary technology platforms to develop next-generation therapies for oncology, infectious diseases, and metabolic disorders while operating a specialized clinical laboratory business. Its value proposition centers on a high-margin specialty diagnostics franchise and a robust pharmaceutical pipeline supported by strategic global partnerships.

Competitive position

Opko maintains a leading position in long-acting growth hormones through its Pfizer partnership and holds a specialized niche in the urology diagnostic market with its proprietary FDA-approved 4Kscore test.

GeographiesUnited States, Ireland, Spain, Mexico, Chile, Israel, China

Customer segmentsHealthcare Providers, Pharmaceutical Companies, Government Agencies, Patients

Business modelProduct-based, Service-based, Licensing and Royalties, Joint Venture

SuppliersRaw material suppliers, Contract manufacturing organizations, Academic research institutions, Specialized laboratory equipment providers

CustomersRetail and specialty pharmacies, Hospital systems, Primary care physicians, Urologists, Public health departments

CountryUnited States of America

Listed1995

Employees3.9K

CEOPhillip Frost

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteopko.com

FilingsSEC EDGAR

Ask your AI about Opko Health.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opko Health's market cap?: Opko Health (OPK) has a market capitalization of $936.3M and trades on NASDAQ.
What is Opko Health's revenue and profitability?: Opko Health generated $587.9M in trailing twelve-month revenue with a net loss of $72.9M, representing a net margin of -12.4%. Gross margin stands at 40.8%, with free cash flow of -$134.0M. These figures are based on the Q2 2026 filing.
Who are Opko Health's competitors?: Opko Health's key competitors include Quest Diagnostics, Bristol-Myers Squibb Co., Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
Who does Opko Health partner with?: Opko Health's notable partners include Pfizer Inc., Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Inc., and others.
What subsidiaries does Opko Health have?: Opko Health's subsidiaries include BioReference Health, LLC, ModeX Therapeutics, Inc., EirGen Pharma, Ltd., and others.
Where is Opko Health headquartered?: Opko Health is headquartered in United States of America and employs approximately 3,930 people. It has been publicly traded since 1995.